新云社 update: Novo Nordisk said China’s National Medical Products Administration has accepted its marketing application for CagriSema (cagrilintide and semaglutide injection) for long-term weight management. The once-weekly subcutaneous fixed-dose combination pairs the long-acting amylin receptor agonist cagrilintide with the GLP-1 receptor agonist semaglutide, which act through different and complementary mechanisms on appetite and body-weight regulation pathways.
China NMPA Accepts Novo Nordisk’s CagriSema Weight-Loss Drug Application
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
43m ago
Argentina approves LNG project under large-investment incentive scheme
52m ago
JackYi: Market Drop Tied to Global Financial Risk, Not Crypto Data
1h ago
NDRC Holds Video Meeting on Government Investment Fund Disbursement and Project Reserves
1h ago
Iran says it shot down 58th US MQ-9 Reaper drone over Strait of Hormuz
1h ago
People’s Daily Rebuts Foreign Pessimism on Chinese Economy
2h ago
Bessent Says He Still Lives on Military Base Over Iran Threats




